世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のモノクローナル抗体市場 2018-2022年

Global Monoclonal Antibodies Market 2018-2022

IRTNTR21977

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年12月US$2,500
シングルユーザライセンス
115

サマリー

この調査レポートは世界のモノクローナル抗体市場を分析・予測したTechNavioの市場調査報告書です。

Description

About this market
Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies. Technavio’s analysts have predicted that the monoclonal antibodies market will register a CAGR of about 15% by 2022.
Market Overview
Introduction of low cost biosimilar monoclonal antibodies
The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.
High cost of monoclonal antibodies
Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.
For the detailed list of factors that will drive and challenge the growth of the monoclonal antibodies market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Johnson & Johnson and Merck the competitive environment is quite intense. Factors such as the rise in the number of companies venturing into monoclonal antibodies space and the introduction of low cost biosimilar monoclonal antibodies, will provide considerable growth opportunities to monoclonal antibodies manufactures. AbbVie, Amgen, Johnson & Johnson, and Merck are some of the major companies covered in this report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY APPLICATION
- Segmentation by application
- Comparison by application
- Oncology - Market size and forecast 2017-2022
- Immunology - Market size and forecast 2017-2022
- Hematology - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by application
PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES
- Segmentation by origin of monoclonal antibodies
- Murine antibodies
- Human antibodies
- Humanized antibodies
- Chimeric antibodies
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: MARKET TRENDS
- Increasing cases of diseases like cancer and immunological disorders
- Rise in the number of companies venturing into the monoclonal antibodies space
- Growing pricing pressure in the monoclonal antibodies segment
PART 15: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- Amgen
- Johnson & Johnson
- Merck
PART 17: APPENDIX
- List of abbreviations

Exhibit 01: Parent market
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Monoclonal antibodies in the pipeline
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global monoclonal antibodies market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global monoclonal antibodies market - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global monoclonal antibodies market by application - Market share 2017-2022 (%)
Exhibit 20: Comparison by application
Exhibit 21: List of monoclonal antibodies approved by FDA/European Medicines Agency post 2015
Exhibit 22: Oncology - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Oncology - Year-over-year growth 2018-2022 (%)
Exhibit 24: Sales of monoclonal antibodies in oncology ($ mn)
Exhibit 25: Immunology - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Sales of monoclonal antibodies for immunology ($ mn)
Exhibit 27: Immunology - Year-over-year growth 2018-2022 (%)
Exhibit 28: Hematology - Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Hematology - Year-over-year growth 2018-2022 (%)
Exhibit 30: Others - Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Sales of monoclonal antibodies in the others segment ($ mn)
Exhibit 32: Others - Year-over-year growth 2018-2022 (%)
Exhibit 33: Market opportunity by application
Exhibit 34: Customer landscape
Exhibit 35: Global monoclonal antibodies market by geography - Market share 2017-2022 (%)
Exhibit 36: Regional comparison
Exhibit 37: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 38: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in Americas
Exhibit 40: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 41: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 42: Top 3 countries in EMEA
Exhibit 43: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 44: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 45: Top 3 countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AbbVie: An overview
Exhibit 52: AbbVie - Business segments
Exhibit 53: AbbVie - Organizational developments
Exhibit 54: AbbVie - Geographic focus
Exhibit 55: AbbVie - Segment focus
Exhibit 56: AbbVie - Key offerings
Exhibit 57: Amgen: An overview
Exhibit 58: Amgen - Business segments
Exhibit 59: Amgen - Organizational developments
Exhibit 60: Amgen - Geographic focus
Exhibit 61: Amgen - Segment focus
Exhibit 62: Amgen - Key offerings
Exhibit 63: Johnson & Johnson: An overview
Exhibit 64: Johnson & Johnson - Business segments
Exhibit 65: Johnson & Johnson - Organizational developments
Exhibit 66: Johnson & Johnson - Geographic focus
Exhibit 67: Johnson & Johnson - Segment focus
Exhibit 68: Johnson & Johnson - Key offerings
Exhibit 69: Merck: An overview
Exhibit 70: Merck - Business segments
Exhibit 71: Merck - Organizational developments
Exhibit 72: Merck - Geographic focus
Exhibit 73: Merck - Segment focus
Exhibit 74: Merck - Key offerings


 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る